Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study

Table 1 Therapy at each stage of stable COPD

Classification	Lung function	Therapy
I: Mild	FEV₁/FVC<0.70, FEV₁≥80% predicted	Active reduction of risk factors; add short-acting bronchodilator (when needed), i.e. albuterol sulfate (inhalation aerosol, Ventolin, GlaxoSmithKline), 100μg/dose, 200 inhalations.
I: Mild	FEV₁/FVC<0.70, FEV₁≥80% predicted	Dosing: 1–2 inhalations of 100 μg each time, and the maximum dose is 8–12 inhalations a day.
II: Moderate	FEV₁/FVC<0.70, 50%≤FEV₁<80% predicted	Based on therapy of GOLD 1; add regular treatment with one long-acting bronchodilators,i.e.formoterol fumarate dehydrate (Inhalation powder, Oxis Turbuhaler, AstraZeneca), 4.5μg/dose, 60 inhalations.
II: Moderate	FEV₁/FVC<0.70, 50%≤FEV₁<80% predicted	Dosing: one inhalation of 4.5μg each time, twice daily
III:Severe	FEV₁/FVC<0.70, 30%≤FEV₁<50% predicted	Based on therapy of GOLD 2; add inhaled glucocorticosteroids if repeated exacerbations,i.e. salmeterol/ fluticasone propionate ([dry powder inhaler], Seretide, GlaxoSmithKline), 50/250 μg/dose, 60 inhalations .
		Dosing: one inhalation of 250/50 μg each time, twice daily

ISSN: 2662-7671